Value of Contrast-enhanced Ultrasound in Sentinel Lymph Node after Primary Breast Cancer Resection
10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.20230523.001
- VernacularTitle:超声造影在乳腺癌原发灶切除后前哨淋巴结的价值
- Author:
Qing-mei MA
1
;
Jia LUO
1
;
Jia-ping LI
1
;
Cai-xin HUANG
1
;
Lai-na WEI
1
;
Ying LIN
2
;
Nan SHAO
2
;
Yan-ling ZHENG
1
Author Information
1. Department of Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China
2. Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China
- Publication Type:Journal Article
- Keywords:
sentinel lymph nodes（SLNs）;
breast cancer;
contrast-enhanced ultrasound（CEUS）
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2023;44(4):663-667
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the value of percutaneous and intravenous contrast-enhanced ultrasound（P-Ⅳ-CEUS） in sentinel lymph nodes（SLNs） after resection of early-stage primary breast cancer. MethodsA retrospective analysis was done on the clinical and imaging data of 42 early breast cancer patients. Following primary tumor resection， all these patients underwent reoperation in our hospital. SLNs were examined by preoperative P-Ⅳ-CEUS and intraoperative sentinel lymph node biopsy（SLNB） was performed by using Methylene blue as a tracer. Then we analyzed the detection and false-negative rate in CEUS and SLNB respectively. By using the surgical pathological results as the gold standard， the diagnostic efficacy of CEUS for SLNs was explored. ResultsThe detection rate and false negative rate of SLNs in percutaneous contrast-enhanced ultrasound （P-CEUS） were 92.9% （39/42） and 7.1% （3/42）， respectively. The detection rate in methylene blue staining was 100% （41/41） and one patient underwent neoadjuvant therapy due to biopsy-confirmed metastasis. The sensitivity， specificity， positive predictive value， negative predictive value and accuracy of P-Ⅳ-CEUS were 66.7% （2/3）， 100% （37/37）， 100% （2/2）， 97.3% （36/37） and 97.4% （38/39）， respectively. ConclusionsP-Ⅳ-CEUS after resection of early-stage primary breast cancer can accurately detect SLNs and characterize their status， which is a reliable clinical basis for reducing invasive SLNB.
